Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Ilieva KM, Correa I, Josephs DH, Karagiannis P, Egbuniwe IU, Cafferkey MJ, Spicer JF, Harries M, Nestle FO, Lacy KE, Karagiannis SN. Ilieva KM, et al. Among authors: spicer jf. Mol Cancer Ther. 2014 Dec;13(12):2769-83. doi: 10.1158/1535-7163.MCT-14-0290. Epub 2014 Nov 10. Mol Cancer Ther. 2014. PMID: 25385327 Free PMC article. Review.
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Karagiannis P, et al. Cancer Immunol Immunother. 2009 Jun;58(6):915-30. doi: 10.1007/s00262-008-0607-1. Epub 2008 Oct 22. Cancer Immunol Immunother. 2009. PMID: 18941743 Free PMC article.
Molecular imaging in clinical trials.
Josephs D, Spicer J, O'Doherty M. Josephs D, et al. Target Oncol. 2009 Sep;4(3):151-68. doi: 10.1007/s11523-009-0117-x. Epub 2009 Sep 21. Target Oncol. 2009. PMID: 19768637 Review.
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, Canevari S, Figini M, Blower PJ, Beavil AJ, Nicodemus CF, Corrigan C, Kaye SB, Nestle FO, Gould HJ, Spicer JF, Karagiannis SN. Rudman SM, et al. Among authors: spicer jf. Clin Exp Allergy. 2011 Oct;41(10):1400-13. doi: 10.1111/j.1365-2222.2011.03770.x. Epub 2011 May 16. Clin Exp Allergy. 2011. PMID: 21569129
Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.
Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ. Karagiannis SN, et al. Among authors: spicer jf. Cancer Immunol Immunother. 2012 Sep;61(9):1547-64. doi: 10.1007/s00262-011-1162-8. Epub 2011 Dec 3. Cancer Immunol Immunother. 2012. PMID: 22139135 Free PMC article. Review.
IgG4 subclass antibodies impair antitumor immunity in melanoma.
Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. Karagiannis P, et al. Among authors: spicer jf. J Clin Invest. 2013 Apr;123(4):1457-74. doi: 10.1172/JCI65579. J Clin Invest. 2013. PMID: 23454746 Free PMC article.
201 results